(R,R)-Formoterol - CAS 67346-49-0
Catalog number: 67346-49-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Adrenergic Receptor
(R,R)-Formoterol is a long acting beta-adrenoceptor agonist acts as a novel highly β2-selective adrenergic agonist and holds promise as a β2-agonist that could impart selective beneficial metabolic effects.
Solid Powder
Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, [R-(R*,R*)]-;4-[(1R)-2-[[(1R)-2-(4-Methoxyphenyl)-1-methylethyl]amino]-1-hydroxyethyl]-2-(formylamino)phenol;N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(αR)-α-methyl-
Soluble in DMSO
Store at -20 °C
A novel highly β2-selective adrenergic agonist
Quality Standard:
Enterprise Standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Canonical SMILES:
Current Developer:
Mylan Specialty
1.The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D1, Schröder-Babo W2, Cohuet G3, Muraro A4, Bonnet-Gonod F3, Petruzzelli S4, Hoffmann M5, Siergiejko Z6; TRIDENT study investigators. Respir Med. 2016 May;114:84-90. doi: 10.1016/j.rmed.2016.03.018. Epub 2016 Mar 26.
This multicentre, double-blind, randomised, placebo-controlled, crossover study aimed to determine the dose-response of the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (GB) when added to beclometasone dipropionate plus formoterol fumarate (BDP/FF) in patients with COPD. Patients received extrafine GB 12.5, 25 or 50 μg twice daily (BID) or placebo for 7 days via pressurised metered dose inhaler (pMDI), and extrafine BDP/FF via pMDI throughout the study. The primary objective was to demonstrate superiority of GB plus BDP/FF versus BDP/FF in terms of FEV1 area under the curve from 0 to 12 h (AUC0-12h) on Day 7. Secondary endpoints included: FEV1 AUC0-12h on Day 1; peak FEV1 and FVC on Days 1 and 7; and trough (12 h post-dose) FEV1, FVC and inspiratory capacity (IC) on Days 1 and 7. Of 178 patients randomised (mean age 62.7 years, post-bronchodilator FEV1 48.9%), 172 (96.6%) completed. Mean FEV1 AUC0-12h on Day 7 was significantly higher (p < 0.
2.Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study.
Fuhr R1, Leselbaum A2, Aubets J3. Clin Pharmacol Drug Dev. 2016 Mar;5(2):109-117. doi: 10.1002/cpdd.209. Epub 2015 Aug 24.
Inhaled, long-acting bronchodilators represent a cornerstone of maintenance treatment for chronic obstructive pulmonary disease (COPD). Aclidinium bromide/formoterol fumarate 400/12 μg fixed-dose combination (FDC) has recently been licensed for use in adults with COPD in the European Union. This phase 1, randomized, open-label, 3-way, complete crossover, single-dose study assessed the pharmacokinetics, safety, and tolerability of an FDC, aclidinium bromide 400 μg, and formoterol fumarate 12 μg, all administered via Genuair™ to 30 healthy subjects. The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively. There were no major differences in relative bioavailability between the combination and monotherapies: the aclidinium Cmax and AUC0-t were 26% and 3% higher, respectively, with aclidinium/formoterol FDC compared with aclidinium alone, and 18% and 11% higher, respectively, compared with formoterol alone.
3.Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease.
Matera MG1, Sanduzzi A2, Cazzola M3. Int J Chron Obstruct Pulmon Dis. 2016 Jan 5;11:73-9. doi: 10.2147/COPD.S78000. eCollection 2016.
Co-administration of a long-acting β2-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting muscarinic antagonist/long acting β2-agonist fixed-dose combination that has been studied for this therapeutic indication.
4.Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
Crisafulli E1, Zanini A2, Pisi G3, Pignatti P4, Poli G5, Scuri M5, Chetta A1. Expert Rev Respir Med. 2016 May;10(5):481-90. doi: 10.1586/17476348.2016.1161508. Epub 2016 Mar 16.
Inhaled therapy is often considered the cornerstone of asthma management and international guidelines recommend combination therapy of inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) in a large proportion of asthmatic patients. The effectiveness of ICS/LABA is dependent on the correct choice of device and proper inhalation technique, this influences drug delivery and distribution along the bronchial tree, including the most peripheral airways. The fixed combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) is the only extrafine formulation available in pressurized metered dose inhaler (pMDI) and in dry powder inhaler (DPI). Here, we focus on the recent significant advances regarding BDP/FF fixed combination for the treatment of asthma.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Adrenergic Receptor Products

CAS 6452-71-7 Oxprenolol

(CAS: 6452-71-7)

Oxprenolol is a lipophilic, non-selective beta-adrenergic blocker. It has some intrinsic sympathomimetic activity and is used for the treatment of angina pector...

CAS 498-45-3 Scopine

(CAS: 498-45-3)

Scopine is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.

(CAS: 211031-01-5)

MK-0634, also called as L-796568, is an β3 adrenergic receptor agonist that was progressed into clinical studies for the treatment of obesity in the early 2000s...

CAS 318-98-9 Propranolol Hydrochloride

Propranolol Hydrochloride
(CAS: 318-98-9)

Propranolol hydrochloride, with antihypertensive, antianginal and antiarrhythmic (class II) properties, is a non-cardioselective adrenergic-beta antagonist and ...

CAS 54239-39-3 Cimbuterol

(CAS: 54239-39-3)

Cimbuterol is a β-adrenergic agonist.

(CAS: 65321-41-7)

MK-761 has beta adrenoceptor antagonist and vasodilating properties in a single molecule. It has beta adrenoceptor blocking activity in the isolated cat heart p...

CAS 74191-85-8 Doxazosin

(CAS: 74191-85-8)

Doxazosin is a quinazoline-derivative and long-lasting α1 adrenergic receptor blocker. It inhibits the binding of norepinephrine, which is released from sympath...

CAS 81732-65-2 Bambuterol

(CAS: 81732-65-2)

Bambuterol is a long acting beta-adrenoceptor agonist (LABA) and is used in the treatment of asthma. It is an ester prodrug of the ß2-adrenergic agonist terbuta...

Chemical Structure

CAS 67346-49-0 (R,R)-Formoterol

Quick Inquiry

Verification code

Featured Items